Fundz

Kinnate Biopharma Inc. reported raising $88 Million in an initial SEC Form D filing, from an offering of $88 Million

PRIVATEAug 04, 2020

Amount Raised

$88 Million

$88 Million sold, per SEC Form D (first sale Aug 4, 2020)

Round Type

Venture

San DiegoBiotechnologyHealthcareHealth CareMedicalTherapeutics

Who else raised in Healthcare and Medical around the same time

Companies in the same sectors as Kinnate Biopharma that raised within 45 days of this round, from Fundz verified event records.

  • Vaccinex raised $2M (Seed) on September 16, 2020.
  • Recursion Pharmaceuticals raised $236M on September 15, 2020.
  • Artivion raised $20M on September 14, 2020.
  • Monteris Medical raised $9M on September 4, 2020.
  • ORTHALIGN INC raised $11M on September 2, 2020.
  • AEON Biopharma raised $25M on August 31, 2020.

Who to call at Kinnate Biopharma, and when

A new round usually means Kinnate Biopharma is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Kinnate Biopharma raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Kinnate Biopharma, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Kinnate Biopharma. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Kinnate Biopharma

Location

San Diego, California, United States

About

Kinnate Biopharma Inc. is a clinical-stage precision oncology company focused on expanding on the promise of targeted therapies for those battling cancer. The company is developing medicines for known oncogenic drivers where there are no approved targeted drugs and to overcome the limitations of marketed cancer therapies, such as non-responsiveness or acquired and intrinsic resistance. Kinnate has two lead clinical programs being studied in solid tumors with RAF, NRAS and FGFR-driven alterations, and is rapidly progressing a pipeline of additional small molecule drug candidates as part of the Kinnate Discovery Engine. The company is driven by the urgency and knowledge that patients are waiting for new, effective cancer medicines. For more information, visit Kinnate.com and follow us on LinkedIn.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Kinnate Biopharma raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Predictive Intelligence
Strategic

ML-powered predictions for Kinnate Biopharma's next move

See what Strategic adds

Kinnate Biopharma raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.